Microbion Corporation

Nov 13, 2024

Microbion Announces Positive Topline Results from Phase 2 Study of Topical Pravibismane for Moderately Infected Diabetic Foot Ulcers

Apr 25, 2024

Microbion Receives Award at Advanced Wound Care Summit USA's Innovation Showcase

Apr 15, 2024

Microbion Selected to Present at Advanced Wound Care Summit USA

Apr 04, 2024

Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal

Jan 30, 2024

Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections

May 28, 2020

Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF

May 27, 2020

Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA